featured
Oral Azacitidine in Patients With Lower-Risk Myelodysplastic Syndromes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
J. Clin. Oncol 2021 Mar 25;[EPub Ahead of Print], G Garcia-Manero, V Santini, A Almeida, U Platzbecker, A Jonasova, LR Silverman, J Falantes, G Reda, F Buccisano, P Fenaux, R Buckstein, M Diez Campelo, S Larsen, D Valcarcel, P Vyas, V Giai, EN Olíva, J Shortt, D Niederwieser, M Mittelman, L Fianchi, I La Torre, J Zhong, E Laille, D Lopes de Menezes, B Skikne, CL Beach, A GiagounidisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.